Status and phase
Conditions
Treatments
About
This is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
226 participants in 2 patient groups
Loading...
Central trial contact
Sherry Zhu, MD, PhD; Catherine Rong
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal